Center for Environmentally Beneficial Catalysis
  • Home
  • Industry liaison torch is passed from Darryl Fahey to Andrzej Rokicki

Industry liaison torch is passed from Darryl Fahey to Andrzej Rokicki

Wednesday, December 10, 2014

The center said goodbye to its former industry liaison director with Darryl Fahey’s retirement last June. Fahey joined CEBC in 2004, after a long and distinguished career at Phillips Petroleum Company and ChevronPhillips Chemicals.

Fahey launched the first formal industry partnership program at KU, which has been held up as a model for the University of Kansas. He recruited more than 20 company members, brought in 70 renowned industry speakers, and mentored dozens of students. As former graduate student Sylvia Nwosu said, “Thank you, Darryl, for always being there! You’ve helped change many lives.”

A new industry liaison director, Andrzej Rokicki, joined CEBC in October. Rokicki has extensive experience developing catalysts from his 25-year career in industry at Scientific Design Inc., United Catalysts/Süd-Chemie, and Air Products & Chemicals. He has commercialized more than 10 catalysts for high-volume chemical processes and has 26 US Patents. “Andrzej is ideally suited to help expand CEBC’s collaborations with industry,” said Bala Subramaniam, CEBC director.



CEBC Calendar

February 6, Tuesday - CEBC Colloquium
Robert Chen, University of Massachusetts

9:00 a.m., CEBC Seminar Room (Bldg B Rm 104), 1501 Wakarusa Drive, Lawrence, KS
Title TBA

February 12, Wednesday - Mandatory Safety Meeting 
9:00 a.m., CEBC Seminar Room (Bldg. B Rm 104)
Presenter: TBD
Topic: 
TBD
This meeting is mandatory for all CEBC researchers working at 1501 Wakarusa

April 6 & 7 - Industry and Science Advisory Boards Spring Meeting
Monday - 10:00 a.m. to 7:00 p.m. at Hilton DoubleTree Hotel, 200 McDonald Drive, Lawrence, KS
Tuesday - 8:00 a.m. to 1:00 p.m. at Hilton DoubleTree Hotel, 200 McDonald Drive, Lawrence, KS

 

KU Today
48 nationally ranked graduate programs.
—U.S. News & World Report
Pharmacy school No. 2 nationally for NIH funding